OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Immsi SpA
SWB:IMY
|
IT |
OSE Immunotherapeutics SA
Other
OSE Immunotherapeutics SA
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Other
€549k
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other
-€19m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other
-€7.9m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-58%
|
|
|
Inventiva SA
PAR:IVA
|
Other
€129m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other
-$345k
|
CAGR 3-Years
8%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Other
-€12.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Other?
Other
549k
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Other amounts to 549k EUR.
What is OSE Immunotherapeutics SA's Other growth rate?
Other CAGR 3Y
31%
Over the last year, the Other growth was 2%. The average annual Other growth rates for OSE Immunotherapeutics SA have been 31% over the past three years .
